Navigation Links
Tarceva Found To Benefit Older Lung Cancer Patients

A new drug has shown promise in the clinical trials involving lung cancer patients and it has even been proposed to evaluate the drug as a frontline therapy for those with lung cancer. One of the significant problems // faced in the treatment regime in the elderly patients is the tolerability and side effects of the drugs currently used.

The tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer according to researchers from Boston.

Erlotinib is designed to specifically and potently block an overactive growth-signaling molecule (EGFR) in cancer cells. The drug has also showed encouraging activity in patients with failed chemotherapy attempts. The present study is the first reported in the assessment of erlotinib in patients who have not received chemotherapy.

The study involved 80 patients with either Stage IIIB or IV presentation who were subjected to erlotinib treatment for 2 years. Almost 60 percent of the patients experienced either a partial response or had stable disease, though none of them had a complete response. The median survival was 46 weeks, and the median duration of partial response and stable disease was 65 weeks and 24 weeks, respectively.

In addition, all patients were evaluated for survival and toxicity; 69 were evaluated for best response. Ten patients discontinued from the study because of toxicity, and there was one treatment-related death from pneumonitis. Rashes (74%) and diarrhea (60 %) were the most common observed side effects.

Following success of the Phase II trials, the Phase III trial would be directed to comparing erlotinib with single-agent navelbine in the above mentioned population shortly.

In conclusion, erlotinib has been found to display encouraging activity and improve median survival in lung cancer patient s. It is also well tolerated in patients over 70 years, a significant finding.

However, further research might be necessary before the drug can be used in the initial treatment of advanced lung cancer rather than approach involving conventional chemotherapy.
'"/>




Related medicine news :

1. Drug Tarceva for End-stage Lung cancer
2. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
3. Fluoride Found Effective in Osteoporosis
4. Implantable Contact Lens Found Safe and Effective
5. Cancer hazard Found With Animal-Based Nutrients
6. Processed Meat, Diabetes connection Found
7. Night Time Aspirin Regimen Found to Reduce Blood Pressure
8. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
9. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
10. Preventive Therapies Found to be More Effective in Managing Migraines
11. Common Cold Found to Fight Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology: